low - Clinical-stage biotechnology companies are largely insulated from GDP fluctuations as they generate no commercial revenue. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) clinical trial enrollment if patients delay elective procedures, and (3) acquisition appetite from potential pharma acquirers. The company's survival depends on capital markets functioning, not economic growth.

Rising interest rates create significant headwinds for pre-revenue biotechs through multiple channels: (1) discount rate impact on NPV of future cash flows increases cost of capital and compresses valuations, (2) reduced investor appetite for speculative growth assets as risk-free rates rise, (3) higher opportunity cost makes cash-burning businesses less attractive versus bonds, and (4) potential acquirers face higher financing costs for M&A. The 10-year Treasury yield directly impacts biotech sector multiples, with 100bp rate increases historically correlating to 15-25% biotech index declines.

growth/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical/regulatory catalysts. Typical shareholders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders pursuing momentum around data readouts. Not suitable for income or value investors given negative cash flow, no dividends, and negative book value. The -36% three-month decline reflects typical volatility around clinical stage setbacks or financing concerns.